A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates

Inclusion criteria

• Adult male or female patients (≥18 years).
• Patients with physician-diagnosed hypertension (as defined by international guidelines including the American Heart Association/American College of Cardiology [AHA/ACC] guidelines and/or the 2024 European Society of Cardiology [ESC] guidelines).
• Patients with documented office blood pressure ≥130/80 mmHg prior to initiating treatment (ARNi or monotherapy) or transitioning from monotherapy to ARNi.
• Patients who are either antihypertensive therapy naïve or currently receiving antihypertensive monotherapy (ACE inhibitor/ARB/CCB) with a physician-directed requirement to transition to ARNi.

Note: Patients who transition from one monotherapy to another during the study are not eligible for inclusion.

• Patients willing to provide written informed consent to participate in the study.

Exclusion criteria

• Patients with malignant or severe hypertension (systolic blood pressure [SBP] ≥180 mmHg, diastolic blood pressure [DBP] ≥110 mmHg) at baseline.
• Patients with secondary causes of hypertension, as determined by the treating physician.
• Patients with a history of, or at risk of developing, angioedema.
• Patients with evidence of severe renal impairment (e.g., estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m^2).
• Pregnant or lactating women.
• Patients with serum potassium level ≥5.5 mmol/L at baseline.